Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. | Available online http arthritis-research.eom content 8 6 R182 Open Access Research article Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis R Andrew Moore and Sheena Derry Pain Research and Nuffield Department of Anaesthetics University of Oxford The Churchill Headington Oxford OX3 7LJ UK Corresponding author R Andrew Moore andrew.moore@pru.ox.ac.uk Received 14 Aug 2006 Revisions requested 19 Sep 2006 Revisions received 23 Oct 2006 Accepted 12 Dec 2006 Published 12 Dec 2006 Arthritis Research Therapy 2006 8 R182 doi 10.1186 ar2093 This article is online at http arthritis-research.com content 8 6 R182 2006 Moore and Derry licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Mycophenolate mofetil MMF is an immunosuppressant drug being used for induction and maintenance of remission of lupus nephritis in systemic lupus erythematosus. Evidence about its use was sought from full publications and abstracts of randomised trials and cohort studies by using a variety of search strategies. Efficacy and adverse event outcomes were sought. Five randomised trials enrolled patients with World Health Organization WHO class III IV or V mostly IV lupus nephritis predominantly comparing MMF 1 to 3 g daily with cyclophosphamide and steroid. Complete response and complete or partial response was significantly more frequent with MMF than with cyclophosphamide with numbers needed to treat of 8 95 confidence interval 4.3 to 60 to induce one additional complete or partial response with wide confidence intervals. Death was reported less frequently with MMF 0.7 1 death in 152 patients than with cyclophosphamide 7.8 12 deaths in 154 patients with a number needed to treat to .
